[1] Rubens RD, Sexton S, Tong D, et al.Combined chemotherapy and radiotherapy for locally advanced breast cancer[J]. Eur J Cancer,1980,16(3):351-356.
[2] Masuda N, Lee SJ, Ohtani S, et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med,2017,376(22):2147-2159.
[3] von Minckwitz GG, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med,2019,380(7):617-628.
[4] Wolmark N, Wang J, Mamounas E, et al.Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr,2001,30:96-102.
[5] Bear HD, Anderson S, Smith RE, et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol,2004,24(13):2019-2027.
[6] Cortazar P, Zhang L, Untch M, et al.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet Oncol,2014,384(9938):164-172.
[7] Minckwitz GV, Kümmel S, Vogel P, et al.Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase Ⅲ randomized GeparTrio trial[J]. J Natl Cancer Inst,2008,100(8):542-551.
[8] Keklikoglou I, Cianciaruso C, Güç E, et al.Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models[J]. Nat Cell Biol,2019,21(2):190-202.
[9] Karagiannis GS, Pastoriza JM, Wang Y, et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism[J]. Sci Transl Med,2017,9(397).pii: eaan0026.
[10] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol,2018,19(1):27-39.
[11] El-Didi MH, Moneer MM, Khaled HM, et al.Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management[J]. Surg Today,2000,30(3):249-254.
[12] Straver ME, Loo CE. Rutgers EJ, et al.MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy[J]. Ann Surg,2010,251(4):701-707.
[13] Marinovich ML, Houssami N, Macaskill P, et al.Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy[J]. J Natl Cancer Inst,2013,105(5):321-333.
[14] Mamounas EP, Anderson SJ, Dignam JJ, et al.Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27[J]. J Clin Oncol,2012,30(32):3960-3966.
[15] Dash N, Chafin SH, Johnson RR, et al.Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer[J]. Am J Roentgenol,1999,173(4):911-917.
[16] Oh JL, Nguyen G, Whitman GJ, et al.Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy[J]. Cancer,2007,110(11):2420-2427.
[17] Pilewskie M, Morrow M.Axillary nodal management following neoadjuvant chemotherapy[J]. JAMA Oncology,2017,3(4):549-555.
[18] Kuehn T, Bauerfeind I, Fehm T, et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol,2013,14(7):609-618.
[19] Boughey JC, Suman VJ, Mittendorf EA, et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA,2013,310(14):1455-1461.
